Take a minute to write an introduction that is short, sweet, and to the point.
Our Team
-
Sabine Goesch, Msc, MBA
Board Member
Chief Executive Officer & CFO
Co-Owner
-
William Fahl, PhD
Board Chairman
Chief Scientific Officer
Co-Founder
-
Peder Andersen, MD
Board Member
Chief Medical Officer
Chief Operations Officer
-
Harri Jarvelainen, DVM, PhD, DABT, ERT
Toxicology
Our Partners
Indication
Radiation
Radiation
Awarded Grants
Mitigation of Radiation-Induced Immune Dysfunction by PrC-210 Treatment.
Synergistic Efficacy of PrC-210 and G-CSF in Conferred Radiation Survival Benefits
Agency
NIH, AFFRI
NIH, CMCRC
$200k
2022 - 2024
Neurodegeneration
Progressing PrC-210 to clinical treatment for the prevention of neurodegenerative diseases after radiation
DOD
$1.1 Mio.
2022 - 2025
Transplantation
Novel Application of PrC-210 aminothiol free-radical scavenger for the protection of vascularized allotransplants
DOD
$1.0 Mio.
2021 - 2025
DOD
Transplantation
PrC-210 for Rapid Limb Stabilization and Protection from Prolonged Ischemia-Reperfusion Injury
$750k
2020 - 2023
DOD
Funding
$2.5 Mio.
Transplantation
Grant Title
Increasing immune tolerance in VCAs with innovative PrC-210 and identifying new corresponding peripheral biomarker for acute and chronic VCA rejection.
$200k
Timeline
2021 - 2027
2022 - 2026